- Home
- EVTV vs APVO Comparison
EVTV vs APVO Comparison
Compare EVTV & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVTV
- APVO
- Stock Information
- Founded
- EVTV 2012
- APVO 2016
- Country
- EVTV United States
- APVO United States
- Employees
- EVTV N/A
- APVO N/A
- Industry
- EVTV Auto Manufacturing
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- EVTV Consumer Discretionary
- APVO Health Care
- Exchange
- EVTV Nasdaq
- APVO Nasdaq
- Market Cap
- EVTV 5.1M
- APVO 4.1M
- IPO Year
- EVTV 2017
- APVO N/A
- Fundamental
- Price
- EVTV $0.20
- APVO $4.95
- Analyst Decision
- EVTV
- APVO Strong Buy
- Analyst Count
- EVTV 0
- APVO 1
- Target Price
- EVTV N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- EVTV 695.4K
- APVO 393.8K
- Earning Date
- EVTV 05-20-2025
- APVO 05-14-2025
- Dividend Yield
- EVTV N/A
- APVO N/A
- EPS Growth
- EVTV N/A
- APVO N/A
- EPS
- EVTV N/A
- APVO N/A
- Revenue
- EVTV $1,650,137.00
- APVO N/A
- Revenue This Year
- EVTV N/A
- APVO N/A
- Revenue Next Year
- EVTV N/A
- APVO N/A
- P/E Ratio
- EVTV N/A
- APVO N/A
- Revenue Growth
- EVTV N/A
- APVO N/A
- 52 Week Low
- EVTV $0.16
- APVO $4.30
- 52 Week High
- EVTV $2.61
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- EVTV 39.85
- APVO 28.32
- Support Level
- EVTV $0.19
- APVO $4.30
- Resistance Level
- EVTV $0.28
- APVO $5.18
- Average True Range (ATR)
- EVTV 0.02
- APVO 1.22
- MACD
- EVTV 0.00
- APVO 0.72
- Stochastic Oscillator
- EVTV 47.37
- APVO 6.47
About EVTV Envirotech Vehicles Inc.
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.